Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for Shield™, the leading blood test for colorectal cancer (CRC) detection and first to receive FDA approval for primary CRC screening, for its achievements in expanding patient choice and increasing screening participation for CRC.
Established in 2007, the Prix Galien USA Awards recognize the leading scientific advances in life sciences that contribute to improving human health worldwide honoring recipients across 8 key categories. Shield was selected as the leading innovation in the medical technology category by a committee of prominent science leaders, Nobel laureates and industry executives.
“Today’s recognition affirms what Shield was designed to do: improve population health by making colorectal cancer screening more accessible,” said AmirAli Talasaz, Guardant Health co-CEO. “Built on more than a decade of pioneering, proprietary innovation in blood-based testing, Shield has continually demonstrated its ability to increase screening adherence in real-world settings, helping more people get screened and advancing our mission to close the nation’s colorectal cancer screening gap.”
Shield is included in both American Cancer Society and National Comprehensive Cancer Network guidelines and is the most clinically validated blood test on the market.
GH shares went skyward $4.83, or 2.8%, to $176.56.
